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The University of North Carolina at Chapel Hill (UNC) is a tertiary-
care, academic university hospital and a major referral center for
patients across the state of North Carolina. This 700-bed, Level 1
trauma center transfuses more than 22,000 RBC units to patients
annually. Clinical services and areas of the hospital which rely most
heavily on transfusion support for their activities are transplan-
tation (bone marrow and solid organ), hematology, critical care
(medical and surgical intensive care units), cardiothoracic surgery,
pediatrics, the operating room, the emergency department, labor
and delivery, dialysis, and outpatient services. UNC is recognized
for its expertise in coagulation, transfusion medicine, and hematol-
ogy, particularly in sickle cell disease (SCD). The sickle cell center
at UNC, which began in 1980 and continues today, in conjunction
with our neighboring institution,Duke University Medical Center, is
designated as part of a National Institutes of Health comprehensive
sickle cell center. Several of the physicians are dedicated to the
care of pediatric and adult patients with SCD, as well as to research
on transfusion management of these patients and recruitment of
African American blood donors. This article describes the practices
of this institution for transfusion management of patients with SCD,
as well as some of its efforts related to this challenging area of
transfusion medicine. Immunohematology 2006;22:103–107.
As a comprehensive sickle cell center (CSSC), the
University of North Carolina at Chapel Hill (UNC)
encounters patients of all ages with a variety of HbS
hemoglobinopathies; the most commonly treated are
patients with Hb SS, Hb SC, and Hb Sβ-thal.
On the basis of the CSSC 2005 census, there were
586 active patients with SCD, or approximately 50 per
month, treated at our institution. Of these, 14 to 15 or
approximately one-third were transfused each month.
This frequency reflects the fact that many patients with
SCD who have complex transfusion needs are
ultimately referred to UNC for management.
Transfusion Therapy for Patients with SCD
Delivery of RBC transfusions to patients with SCD
varies by method (simple vs. exchange) and frequency
(episodic vs. chronic). In evaluating the need for
simple versus exchange transfusion, a number of
important factors should be considered. These include
the acuity of anemia, the patient’s baseline Hct prior to
presenting for treatment, and the urgency of the need
for oxygen-carrying capacity. Simple transfusions are
often helpful as a first step to increase the oxygen-
carrying capacity in a stable patient who presents with
symptomatic anemia when such transfusions would
increase the patient’s Hct to a maximum of 33 percent.
The rheology of SCD is such that, above this
threshold, complications from hyperviscosity may
become a problem. When hyperviscosity or volume
overload or both are a concern, or when a patient
presents with life- or organ-threatening disease, ex-
change transfusion is the preferred method. Emergent
automated exchanges are therefore performed for a
variety of the indications in SCD, including stroke,
acute chest syndrome, and hepatic sequestration. The
goal of transfusion is to reduce HbS to 10 to 30
percent, depending on the clinical setting.
Also in place at UNC is a chronic RBC exchange
program that has enrolled about 40 patients cumula-
tively since 1996 and currently has 20 active patients,
the majority of whom are pediatric (65%). These
patients are managed with apheresis RBC exchanges.
Exchange transfusions and iron chelation therapy are
the only two methods known to prevent iron overload
patients receiving chronic transfusion therapy.1 At our
institution, pediatric patients with abnormal trans-
cranial Doppler studies who are at risk for stroke and
those with a history of stroke receive exchange trans-
fusion in accordance with the STOP trials.2,3 These
patients will potentially receive life-long RBC exchange
transfusions as new data indicate that their risk of
stroke reverts back to baseline if transfusion therapy is
stopped.4 We are also part of the multi-institutional,
ongoing clinical trial that uses exchange transfusion for
pediatric patients with SCD and silent infarcts (silent
infarct and transfusion trial: SIT). Although the use of
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chronic transfusion therapy in adults after stroke has
not been systematically studied, we perform RBC
exchanges prophylactically in this setting. Other uses
of chronic RBC exchange in our population include
recurrent priapism and pulmonary hypertension in
adults.
Other circumstances in which transfusion therapy
is used include preoperative management of patients
and pregnancy. In the former case, manual exchange is
performed by the phlebotomy of 1 unit of RBCs
followed by the simple transfusion of 1 to 2 units of
RBCs to achieve a Hct of 33 percent. In the latter,
transfusions are only used when a pregnancy is at risk
because of SCD complications, with goals similar to
those for a nonpregnant patient. We typically do not
perform transfusions for patients with SCD who have
controversial indications, such as recurrent nonhealing
leg ulcers and debilitating pain, and before the use of
IV contrast media.5
Transfusion Protocol 
Because of the expertise of our health care
providers and the frequency with which patients with
SCD are transfused at our facility, the overall environ-
ment is favorable for reliable communication and
consistent transfusion practice for these patients.
Familiarity with the special requirements and trans-
fusion complications in this patient population makes
clear the need for appropriate identification of these
patients before transfusion.
The blood component order form is an important
tool that allows a physician to indicate the diagnosis of
SCD and request special transfusion needs. Verbal
communication of patient diagnosis or component
attributes may also occur. This information is crucial
for encounters with new patients without a prior
history at our institution or blood bank. The blood
bank history review, which occurs before patient
testing, will also identify samples from patients with
SCD in the laboratory. Some patients are recognized by
name by virtue of the frequency of their visits or the
complexity of their serologic testing.
Patient testing
Routine serologic testing on samples from patients
with SCD is the same as that for any potential
transfusion recipient; this testing includes ABO and D
typing and antibody detection and identification, if
necessary. Typing of the RBCs of these patients for C,
E, c, e, K, Fya, Fyb, M, N, S, s, P1, Lea, and Leb antigens is
routinely performed when they are initially seen at our
facility. Records from a referring facility may be helpful
in instances where phenotyping is not possible or if
transfusion of RBCs is urgently needed. If RBC trans-
fusion has occurred recently, a hypotonic saline
washing procedure can be performed to lyse allo-
geneic RBCs containing HbA to allow phenotyping of
autologous RBCs.
Selection of RBC units for transfusion
All units of RBCs are prestorage leukocyte-reduced
and ABO and D compatible with the patient’s blood
type. As inventory allows, units are selected that have
been stored 14 days or less. Pretransfusion prophy-
lactic phenotype matching is routinely and consistently
performed for C, E, and K. If other clinically significant
antibodies are present in the patient’s plasma, or are
historically known, appropriate antigen-negative RBCs
are selected in addition to those typed as C–, E–, and
K–. HbS testing of RBCs (Sickle Dex, Ortho-Clinical
Diagnostics, Raritan, NJ) is performed when requested
by the clinician or automatically for apheresis RBC
exchange procedures. To calculate accurate RBC
replacement volumes for these exchanges, quantitative
Hb electrophoresis is performed.
Rationale
The rationale for pretransfusion prophylactic
phenotype matching for C, E, and K is related to the
immunogenicity of these antigens. The overall
alloimmunization rate for chronically transfused
patients with SCD is much higher than that for other
similarly transfused populations, estimated at 25 to 30
percent.6–9 While the majority of these patients will not
form antibodies, those that do may experience
complications including hemolytic transfusion reac-
tions, stimulation of sickle cell crises, and increased
difficulty of finding compatible RBCs when needed in
the future. A general cautious approach at our institu-
tion has been shaped by the clinical experience of
managing more severe transfusion complications in
patients with SCD, such as hyperhemolysis. Because it
is relatively easy to select C–, E–, and K– units from our
general inventory,we can effectively prevent alloimmu-
nization to these most immunogenic antigens.6–9
Although alloimmunization rates of these patients at
our institution have not been specifically measured, the
occurrence of new antibodies is infrequent and
certainly less than 25 percent for those patients
transfused exclusively at our facility. However, newly
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identified antibodies directed against low-incidence
antigens, such as Jsa, and warm autoantibodies do
occur. On occasion, patients are transfused elsewhere
without partial phenotype matching and then
transferred to our facility. In this setting, we have seen
sensitization to Rh and Kell antigens and, less
commonly, delayed transfusion reactions because of
anti-S, anti-Jka, and anti-Jkb. Sensitization to the latter
antigens is also a possibility at our facility because we
do not routinely provide RBCs negative for these
antigens unless the plasma had a broadly reactive warm
autoantibody or there was a previously identified
alloantibody.
Special considerations
Extended phenotype matching is performed
whenever possible in patients with SCD with warm
autoantibodies, especially when the autoantibody is
causing hemolysis. If the warm-reactive autoagglutinin
is not associated with hemolysis, phenotype matching
of RBCs is limited to C, E, and K and those indicated by
antibody identification. Units for transfusion are
selected on the basis of compatibility tests showing
reactivity no stronger than those with the autologous
RBCs.
For patients with antibodies to low-incidence
antigens, RBCs for transfusion are selected on the basis
of their compatibility by the IAT. If the antibody is no
longer detectable and has an identified specificity,
antigen-negative RBCs are requested from our blood
supplier in advance. If appropriate antisera are not
available to type units, RBCs are accepted from donors
on the basis of historic antigen typing. If there is
insufficient time for these pretransfusion steps, the
ordering physician signs a conditional release card that
provides documentation of his recognition of a
possible, albeit unlikely, anamnestic immune response
if the patient is re-exposed to the low-incidence
antigen. This ensures that a proper risk and benefit
assessment is made and also provides the opportunity
for the blood bank physician to communicate with and
educate the ordering physicians.
Our interest in blood bank practices for patients
with SCD prompted systematic inquiry at the state and
national level. We conducted a cross-sectional survey
of North Carolina hospitals with blood bank facilities to
assess hospital and patient demographics,as well as the
services, testing, and blood components offered to
patients with SCD.10 Data from 76 of 106 (70%)
hospitals showed the majority to be community
hospitals (90%) whose blood banks saw a wide range
of patients with SCD each month (0 to 30;median = 1).
While all provided simple transfusion services, only 16
percent performed exchange transfusions, and 7
percent provided chronic transfusion programs. Less
than one-third (29%) of these hospital blood banks had
specific policies or procedures for patients with SCD.
Less than one-half routinely provided HbS-negative
RBCs (42%). With respect to the use of phenotype-
matched RBCs, 38 percent provided antigen-matched
RBCs, but only one-half (17%) did this prophylactically.
Those providing phenotype-matched RBCs were more
likely (p < 0.001) to have a trauma center (84% vs.
25%), to have policies for work-ups for patients with
SCD (77% vs. 19%), to perform routine RBC pheno-
typing (50% vs. 4%), and to provide HbS-negative RBCs
(65% vs. 16%).
We also conducted a national survey of major
academic medical centers to ascertain current prac-
tices in selecting RBCs for the transfusion of patients
with SCD.11 Thirty-seven of 50 (74%) centers
responded. The majority did perform partial pheno-
type matching of RBCs; however, a specific standard of
care was not apparent. The most common antigens
matched prophylactically were:E (73%),K (70%),and C
(68%), followed by c (41%), and e (41%). There were
also differences in transfusion practices for pediatric
versus adult patients with SCD. Because of our
experience, published data, and the results of these
surveys,we continue to advocate the standardization of
SCD transfusion practice to guide health care providers
at both major academic medical centers as well as
community-based hospitals.
Blood Supply Issues
Providing blood to this population can be
challenging. Although the majority of patients do not
form antibodies, those that do can present a problem in
finding compatible RBCs. As a group, patients with
SCD are the largest users of the national rare blood
inventory, using up to one-third of the rare blood
supply.12 Therefore,excellent communication between
our hospital transfusion service and our regional blood
supplier is essential.
To fill that need, we have developed several
strategies with our blood supplier. These include on-
demand 24-hour access to units with special attributes
for emergent indications and the ability to discuss
special needs with either a reference laboratory
specialist or the blood supplier’s medical director.
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RBCs for scheduled automated exchanges are ordered
in advance and arrive in time for HbS testing and
crossmatching at our facility. Our blood supplier
provides reliable and safe blood resources and,with the
added service of an advanced reference laboratory,
even our most complex transfusion recipients can be
managed appropriately.Nonetheless, the need for more
active recruitment of donors within the African
American community still exists.
A few centers that specialize in treating patients
with SCD in conjunction with their regional blood
collection facilities have begun programs to actively
recruit and retain African American donors for their
patients with SCD. These programs have mostly
focused on matching these donors with the transfusion
needs of their pediatric population. African American
donors are asked to donate up to four times a year for
the patients with SCD with whom they are matched.
The degree of matching varies. Most of these centers
provide C-, E-, and K-matched RBCs for these patients
and have a readily available inventory in which to find
rare RBCs. Others have attempted to provide
extended, phenotypically matched RBCs for all of the
transfusion needs of these patients. These types of
programs require extensive commitment on the part of
the blood center to coordinate donor collections with
patient transfusion needs; staffing, donor recruitment,
and donor retention are critical. The success of such
programs in improving transfusion care to patients
with SCD appears anecdotally to be good, decreasing
alloimmunization rates in the short term. However,
long-term effects have not been studied.
In our region, no specific donor recruitment
process exists except on a local level. One of our
institutional goals is to develop an active recruitment
and retention program to match African American
donors and patients with SCD, focusing our
recruitment on donors at the 11 historically black
colleges and universities (HBCUs) in our state. The
HBCUs are a potentially rich source of African
American donors that to date have been underused.
Currently, one such program at a local HBCU has been
widely successful in recruiting and retaining African
American donors and has been cited by the American
Red Cross as “a model for colleges and universities
nationwide.”13 Active research is ongoing with this
institution in an attempt to learn and understand the
key components that have made it successful, and to
adopt these components into a workable program that
can be used at other institutions in our state.14
Conclusions
Patients with SCD provide many challenges for the
field of blood banking and transfusion medicine. Our
institution has taken a number of steps to ensure that
practices here are consistent with national recommen-
dations. We are fortunate to have a reliable blood
supplier to facilitate the standard of care adopted at
this center and we are pleased with the strides to
examine SCD transfusion practices at the local, state,
and national levels. There remains a need to standard-
ize practices to minimize morbidity associated with
transfusion in this population. Efforts need to be
directed at academic medical centers, but must also
reach community-based hospitals where many of these
patients present during crises. Accomplishing this goal
will ultimately require consensus within the blood
banking community and recruitment of donors who
can best meet the RBC phenotype needs of these
patients.
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